Business Context and Reporting Period
Company: Skye Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 3, 2024
Reporting Period: The filing addresses events occurring after the fiscal year-end of December 31, 2023, specifically focusing on compliance with Nasdaq Capital Market listing requirements.
Key Financial Metrics
This filing does not report standard operating metrics such as revenue, profit, or cash flow for a specific period. Instead, it presents an unaudited pro forma balance sheet as of December 31, 2023, adjusted for subsequent events to demonstrate compliance with the minimum $5 million stockholders' equity requirement for initial listing on The Nasdaq Capital Market.
- Stockholders' Equity: Management states that as of the date of this Form 8-K, stockholders' equity exceeds $5 million.
- Source of Adjustments: The pro forma figures incorporate proceeds from private placement transactions closed on January 31, 2024, and March 13, 2024, as well as proceeds from a real estate sale on January 19, 2024.
Material Changes Versus Prior Period
The filing highlights material changes to the company's financial position occurring between December 31, 2023, and April 3, 2024, which are not reflected in the audited 10-K filed on March 22, 2024:
- Capital Raises: Receipt of proceeds from private placement securities sales in January and March 2024.
- Asset Disposition: Sale of real estate on January 19, 2024.
- Equity Position: These events collectively increased stockholders' equity to meet the $5 million threshold required for Nasdaq listing.
Guidance, Outlook, and Risks
Management Commentary: The primary purpose of this disclosure is to evidence compliance with Nasdaq listing standards. The company asserts that the pro forma adjustments confirm its eligibility for the Nasdaq Capital Market.
Limitations: The filing explicitly states that the unaudited pro forma balance sheet is for informational purposes only and should be read in conjunction with the audited financial statements in the Form 10-K. The information is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other registration statements unless expressly stated.
Risks and Contingencies: No specific new risks or contingencies are detailed in this text beyond the implicit risk of failing to meet listing requirements, which the company claims to have resolved.
Investor Verification Checklist
- Verify the exact amount of proceeds received from the private placements on January 31, 2024, and March 13, 2024, by reviewing the referenced Form 10-K Note 14.
- Confirm the net proceeds from the real estate sale on January 19, 2024, and any associated tax or transaction costs.
- Review the audited Form 10-K filed on March 22, 2024, to compare the pre-adjustment stockholders' equity against the pro forma figures.
- Monitor subsequent filings to confirm the official listing status on The Nasdaq Capital Market.